Please use this identifier to cite or link to this item: https://ahro.austin.org.au/austinjspui/handle/1/16133
Full metadata record
DC FieldValueLanguage
dc.contributor.authorYeap, Bu Ben_US
dc.contributor.authorGrossmann, Mathisen_US
dc.contributor.authorMcLachlan, Robert Ien_US
dc.contributor.authorHandelsman, David Jen_US
dc.contributor.authorWittert, Gary Aen_US
dc.contributor.authorConway, Ann Jen_US
dc.contributor.authorStuckey, Bronwyn GAen_US
dc.contributor.authorLording, Douglas Wen_US
dc.contributor.authorAllan, Carolyn Aen_US
dc.contributor.authorZajac, Jeffrey Den_US
dc.contributor.authorBurger, Henry Gen_US
dc.date15-08-2016en_US
dc.date.accessioned2016-08-16T03:21:17Z-
dc.date.available2016-08-16T03:21:17Z-
dc.date.issued2016-08-15-
dc.identifier.citationMedical Journal of Australia 2016; 205(4): 173-178en_US
dc.identifier.urihttps://ahro.austin.org.au/austinjspui/handle/1/16133-
dc.description.abstractThis article, Part 1 of the Endocrine Society of Australia's position statement on male hypogonadism, focuses on assessment of male hypogonadism, including the indications for testosterone therapy. (Part 2 will deal with treatment and therapeutic considerations.)en_US
dc.description.abstractMAIN RECOMMENDATIONS:en_US
dc.description.abstractKey points and recommendations are:Pathological hypogonadism arises due to diseases of the hypothalamus or pituitary gland (hypogonadotropic hypogonadism) or testes (hypergonadotropic hypogonadism). It is a clinical diagnosis with a pathological basis, confirmed by hormone assays.Hormonal assessment is based on measurement of circulating testosterone, luteinising hormone (LH) and follicle-stimulating hormone (FSH) concentrations. Measurement of sex hormone-binding globulin levels can be informative, but use of calculated free testosterone is not recommended for clinical decision making.Testosterone replacement therapy is warranted in men with pathological hypogonadism, regardless of age.Currently, there are limited data from high-quality randomised controlled trials with clinically meaningful outcomes to justify testosterone treatment in older men, usually with chronic disease, who have low circulating testosterone levels but without hypothalamic, pituitary or testicular disease.Obesity, metabolic syndrome and type 2 diabetes are associated with lowering of circulating testosterone level, but without elevation of LH and FSH levels. Whether these are non-specific consequences of non-reproductive disorders or a correctable deficiency state is unknown, but clear evidence for efficacy and safety of testosterone therapy in this setting is lacking.Glucocorticoid and opioid use is associated with possibly reversible reductions in circulating testosterone level, without elevation of LH and FSH levels. Where continuation of glucocorticoid or opioid therapy is necessary, review by an endocrinologist may be warranted.Changes in management as result of the position statement: Men with pathological hypogonadism should be identified and considered for testosterone therapy, while further research is needed to clarify whether there is a role for testosterone in these other settings.en_US
dc.language.isoenen_US
dc.titleEndocrine Society of Australia position statement on male hypogonadism (part 1): assessment and indications for testosterone therapyen_US
dc.typeJournal Articleen_US
dc.identifier.affiliationUniversity of Western Australia, Perth, Western Australia, Australiaen_US
dc.identifier.affiliationAustin Health, The University of Melbourne, Heidelberg, Victoria, Australiaen_US
dc.identifier.affiliationHudson Institute of Medical Research, Melbourne, Victoria, Australiaen_US
dc.identifier.affiliationANZAC Research Institute, University of Sydney, Sydney, NSW, Australiaen_US
dc.identifier.affiliationUniversity of Adelaide, Adelaide, South Australia, Australiaen_US
dc.identifier.affiliationRoyal Adelaide Hospital, Adelaide, South Australia, Australiaen_US
dc.identifier.affiliationKeogh Institute for Medical Research, Sir Charles Gairdner Hospital, Perth, Western Australia, Australiaen_US
dc.identifier.affiliationCabrini Hospital, Melbourne, Victoria, Australiaen_US
dc.identifier.pubmedurihttps://pubmed.ncbi.nlm.nih.gov/27510348en_US
dc.identifier.doi10.5694/mja16.00393en_US
dc.type.contentTexten_US
dc.type.austinJournal Articleen_US
local.name.researcherGrossmann, Mathis
item.openairecristypehttp://purl.org/coar/resource_type/c_18cf-
item.cerifentitytypePublications-
item.fulltextNo Fulltext-
item.grantfulltextnone-
item.languageiso639-1en-
item.openairetypeJournal Article-
crisitem.author.deptEndocrinology-
crisitem.author.deptEndocrinology-
crisitem.author.deptMedicine (University of Melbourne)-
Appears in Collections:Journal articles
Show simple item record

Page view(s)

10
checked on Mar 28, 2024

Google ScholarTM

Check


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.